Healthcare Sales & Marketing Network News: Pioglitazone

Searching News Database: Pioglitazone

HSMN NewsFeed - 8 Feb 2018
ZYTIGA(R) (abiraterone acetate) Plus Prednisone Approved for Treatment of Earlier Form of Metastatic Prostate Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 17 Aug 2017
Hikma Announces Expanded Licensing Agreement with Takeda for New Products in the Middle East and North Africa
Biopharmaceuticals Licensing Distribution

HSMN NewsFeed - 5 Aug 2015
Metacrine Raises $36 Million in Series A Financing
Biopharmaceuticals Venture Capital Personnel

HSMN NewsFeed - 8 Apr 2014
Takeda Responds to Verdict in Diabetes Drug Case
Biopharmaceuticals Endocrinology Litigation

HSMN NewsFeed - 3 Mar 2014
U.S. FDA Approves Bydureon(R) Pen (exenatide extended-release for injectable suspension) for Once-Weekly Treatment of Adults with Type 2 Diabetes
Biopharmaceuticals Drug Delivery Endocrinology FDA

HSMN NewsFeed - 18 Dec 2013
Takeda Launches New Subsidiary in Israel
Biopharmaceuticals

HSMN NewsFeed - 18 Dec 2012
FDA Clears IND For First Clinical Trial Protocol Developed Using Crowdsourcing
Biopharmaceuticals Neurology FDA

HSMN NewsFeed - 17 Aug 2012
Ranbaxy Launches Authorized Generic Of Pioglitazone In The U.S.
Biopharmaceuticals Generics Endocrinology

HSMN NewsFeed - 23 Mar 2012
BYETTA(R) Approved for Use with Basal Insulin in Europe
Biopharmaceuticals Endocrinology Regulatory

HSMN NewsFeed - 23 Sep 2010
Takeda Responds to Announcement about Suspension of Rosiglitazone Marketing Authorization in Europe and Restrictions in the U.S.
Biopharmaceuticals Endocrinology Regulatory

HSMN NewsFeed - 29 Apr 2010
Ipsen's Partner Roche Announces That Taspoglutide Meets Its Primary Endpoint in a Key Phase III Clinical Trial
Biopharmaceuticals Endocrinology

HSMN NewsFeed - 28 Apr 2010
Takeda Provides Update on Patent Litigation for ACTOS(R) (pioglitazone HCl) and ACTOplus met(R) (pioglitazone HCl and metformin HCl) in the U.S.
Biopharmaceuticals Litigation Endocrinology

HSMN NewsFeed - 15 Mar 2010
Ranbaxy Announces Settlement of Actos(R) (Pioglitazone Hydrochloride) Patent Litigation
Biopharmaceuticals Generics Litigation

HSMN NewsFeed - 10 Mar 2010
Watson Announces Actos(R) Patent Challenge Settlement
Biopharmaceuticals Generics Litigation

HSMN NewsFeed - 9 Jun 2009
Roche to Commence Phase III Trials with Innovative Treatment Designed to Lower Cardiovascular Risk in Diabetes Patients with Recent Heart Attack
Biopharmaceuticals Endocrinology Cardiology

HSMN NewsFeed - 13 May 2009
FDA Approves ACTOplus met(R) XR (pioglitazone HCl and metformin HCl extended-release) Tablets for the Treatment of Type 2 Diabetes
Biopharmaceuticals Endocrinology FDA

HSMN NewsFeed - 26 Jan 2009
Amylin Pharmaceuticals Appoints Vincent Mihalik Senior Vice President, Sales and Marketing and Chief Commercial Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 31 Mar 2008
New Data Showed ACTOS(R) (pioglitazone HCl) Prevented Progression of Atherosclerotic Plaque Volume in Patients With Type 2 Diabetes
Biopharmaceuticals Cardiology Endocrinology

HSMN NewsFeed - 11 Dec 2007
GlaxoSmithKline Responds to JAMA Article on the ICES Thiazolidinediones and Cardiovascular Outcomes in Older Patients with Diabetes
Biopharmaceuticals Endocrinology Cardiology

HSMN NewsFeed - 17 Oct 2007
FDA Approves Supplemental New Drug Applications for JANUVIA(TM) (sitagliptin)
Biopharmaceuticals Endocrinology FDA

HSMN NewsFeed - 19 Sep 2007
ACTOS(R) (pioglitazone HCl) Demonstrates Reduced Risk of Ischemic Cardiovascular Disease in Patients With Type 2 Diabetes
Biopharmaceuticals Endocrinology Cardiology

HSMN NewsFeed - 11 Sep 2007
Cleveland Clinic Study Shows the Diabetes Drug Pioglitazone Reduces Risk of Death, Heart Attack and Stroke, but Increases Risk of Heart Failure
Biopharmaceuticals Endocrinology Cardiology

HSMN NewsFeed - 11 Sep 2007
Takeda Statement on ACTOS(R) (pioglitazone HCl) Meta-Analysis Published in the Journal of the American Medical Association
Biopharmaceuticals Endocrinology Cardiology

HSMN NewsFeed - 11 Sep 2007
GlaxoSmithKline Responds to JAMA Articles
Biopharmaceuticals Endocrinology Cardiology

HSMN NewsFeed - 31 Jul 2007
Endocrinologists Welcome FDA Avandia Recommendation
Biopharmaceuticals Endocrinology Cardiology FDA

HSMN NewsFeed - 23 Jun 2007
Results of Two Head-to-Head Studies Demonstrated Long-Acting Insulin Lantus(R) Lowered Free Fatty Acid Levels Equal to or Better Than Thiazolidinediones
Biopharmaceuticals Endocrinology

HSMN NewsFeed - 6 Jun 2007
Takeda Revises ACTOS(R) (pioglitazone HCl) Prescribing Label
Biopharmaceuticals Endocrinology FDA

HSMN NewsFeed - 15 May 2007
Array BioPharma Appoints John Yates, MB ChB, MD, to Chief Medical Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 19 Jan 2007
Takeda Global Research & Development Center, Inc. Names Dr. Mehmood Khan President
Biopharmaceuticals Personnel

HSMN NewsFeed - 13 Nov 2006
New Data Show ACTOS(R) (pioglitazone HCl) Halted Progression of Atherosclerosis as Indicated by CIMT in Patients With Type 2 Diabetes
Biopharmaceuticals

HSMN NewsFeed - 17 Oct 2006
FDA Approves Once-Daily JANUVIA(TM), the First and Only DPP-4 Inhibitor Available in the United States for Type 2 Diabetes
Biopharmaceuticals FDA Endocrinology

HSMN NewsFeed - 14 Sep 2006
ACTOS(R) (pioglitazone HCl) Demonstrates Significant Improvements in Cardiovascular Outcomes for High-Risk Patients With Type 2 Diabetes
Biopharmaceuticals Endocrinology Cardiology

HSMN NewsFeed - 3 Sep 2006
New Analyses Show ACTOS(R) (pioglitazone HCl) Reduced Risk of Secondary Stroke by Almost 50 Percent in High-Risk Type 2 Diabetes Patients
Biopharmaceuticals Endocrinology

HSMN NewsFeed - 31 Jul 2006
FDA Approves duetact(TM) (pioglitazone HCl and glimepiride) for the Treatment of Type 2 Diabetes
Biopharmaceuticals Endocrinology FDA

HSMN NewsFeed - 21 Jul 2006
Takeda Announces Start of Phase 3 Clinical Program in the U.S. of Fixed Dose Combination Product of Actos(R) + TAK-536 for Treatment of Patients with Type 2 Diabetes Associated with Hypertension
Biopharmaceuticals Endocrinology Cardiology

HSMN NewsFeed - 13 Jun 2006
In New Data at One Year, JANUVIA(TM), an Investigational Medicine for Type 2 Diabetes, Demonstrated Substantial Glucose-Lowering Effect, with Significant Differences Compared to Glipizide (a Sulfonylurea) in Weight Change and Hypoglycemia
Biopharmaceuticals Endocrinology

HSMN NewsFeed - 13 Jun 2006
Novartis Unveils Further Impressive Efficacy Data for Galvus(R), an Investigational Oral Diabetes Compound, Showing Significant Blood Sugar Reductions
Biopharmacetuicals Endocrinology

HSMN NewsFeed - 4 Apr 2006
Andrx Announces Filing of NDA by Takeda for ACTOS and Extended-Release Metformin Combination Product
Biopharmaceuticals Endocrinology

HSMN NewsFeed - 3 Apr 2006
Takeda Submits New Drug Application for Extended-Release Type 2 Diabetes Medication, ACTOplus met(TM) (pioglitazone HCl and metformin HCl)
Biopharmaceuticals Endocrinology

HSMN NewsFeed - 22 Feb 2006
Takeda Wins Patent Infringement Litigation Against ANDA Filers for Generic ACTOS(R) (pioglitazone HCl)
Biopharmaceuticals Generics Litigation

Return to NewsFeed

Additional items found! 29

Members: click here for search results from The HSMN Archive (password required)

Members Archive contains 29 additional stories matching:
Pioglitazone
(Password required)

FindReps - Find Great Medical Independent Sales Reps without recruiter fees.

FindReps - available on the Apple App Store for iPhone and iPad.